巨头赛诺菲:Dupilumab业绩高涨94%;过专利药物迎来黄昏
2023-08-05 22:00
举报
Dupixent(IL-4R a)业绩为16.34亿欧元,同比大增93.8%;Praluent(PCSK9)业绩仅为1.46亿欧元,同比增长18%;波立维Plavix业绩为5....
相关阅读
2021-09-18
2021-04-13
2021-12-09
2021-04-23
2021-09-13
2021-12-27
2021-12-31
2022-01-10
2021-12-10
2022-01-14
2021-10-28
2022-07-28
